Skip to main content
OpenTrials
Completed

NCT Number: NCT06405737

Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, 611731, China

About this study

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects without past or current psychiatric or neurological disorders

Exclusion criteria

  • history of head injury
  • pregnant,menstruating,taking oral contraceptives
  • medical or psychiatric illness.
  • excessive head movement (> 3mm) during scanning

Treatment and study plan

Intranasal oxytocin

Drug

Subject assigned to receive intranasal administration of oxytocin (24 IU).

Intranasal placebo

Drug

Subjects assigned to receive intranasal administration of placebo (24 IU).

Primary outcomes

  1. Behavioral index: fairness rating scores

    Time frame: 45-75 minutes after treatment administration

    Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair).

  2. Behavioral index: preference rating scores

    Time frame: 45-75 minutes after treatment administration

    Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable).

  3. Neural indices: fMRI-based measures of the outcome presentation stage

    Time frame: 45-75 minutes after treatment administration

    Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair).

Secondary outcomes

  1. Behavioral index: choice rate of unequal option

    Time frame: 45-75 minutes after treatment administration

    Participants are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.

  2. Neural indices: fMRI-based measures of outcome and re-decision stages

    Time frame: 45-75 minutes after treatment administration

    Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.

Sponsors and collaborators

Lead sponsor

University of Electronic Science and Technology of China

Other

Registry information

Official study title

Oxytocin Modulates the Processing of the Advantageous- and Disadvantageous-inequity

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
May 8, 2024
Registry last updated
Aug 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.